2024/10/18 更新

写真a

ヨシオ コウタロウ
吉尾 浩太郎
YOSHIO Koutarou
所属
医歯薬学域 講師(特任)
職名
講師(特任)
外部リンク

学位

  • 博士(医学) ( 岡山大学 )

 

論文

  • Outcomes of solitary postoperative recurrence of esophageal squamous cell carcinoma diagnosed with FDG-PET/CT and treated with definitive radiation therapy.

    Hiroki Ihara, Kotaro Yoshio, Shunsuke Tanabe, Soichi Sugiyama, Masashi Hashimoto, Naoaki Maeda, Shinsuke Akagi, Soshi Takao, Kazuhiro Noma, Takao Hiraki

    Esophagus : official journal of the Japan Esophageal Society   20 ( 3 )   548 - 556   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Surgical resection of esophageal cancer is frequently performed to achieve a complete cure. However, the postoperative recurrence rate is 36.8-42.5%, leading to poor prognosis. Radiation therapy has been used to treat recurrences; solitary recurrence has been proposed as a prognostic factor for radiation therapy, though its significance is unclear. 18F-fluorodeoxyglucose positron emission tomography is a highly accurate diagnostic modality for esophageal cancer. This retrospective study aimed to analyze the outcomes of solitary postoperative recurrences of esophageal squamous cell carcinoma diagnosed with 18F-fluorodeoxyglucose positron emission tomography and treated with definitive radiation therapy. METHODS: We examined 27 patients who underwent definitive radiation therapy for single or multiple postoperative recurrences of esophageal squamous cell carcinoma between May 2015 and April 2021. 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed within 3 months before the commencement of radiation therapy. Kaplan-Meier, univariate, and multivariate analyses were performed to examine the overall survival and identify potential prognostic factors. RESULTS: The 1-, 2-, and 3-year overall survival rates were 85.2%, 62.6%, and 47.3%, respectively, and solitary recurrence was the only significant factor associated with overall survival (P = 0.003). The 1-, 2-, and 3-year overall survival rates in patients with solitary recurrence were 91.7%, 80.2%, and 80.2%, respectively, and in patients with multiple recurrences they were 80.0%, 50.3%, and 25.1%, respectively. Multivariate analysis also showed solitary recurrence as a significant factor for overall survival. CONCLUSIONS: When diagnosed with 18F-fluorodeoxyglucose positron emission tomography/computed tomography, solitary recurrence appears to have a more favorable prognosis than multiple recurrences.

    DOI: 10.1007/s10388-023-01000-4

    PubMed

    researchmap

  • Tumor size before image-guided brachytherapy is an important factor of local control after radiotherapy for cervical squamous cell carcinoma: analysis in cases using central shielding. 国際誌

    Kotaro Yoshio, Hiroki Ihara, Kazuhiro Okamoto, Etsuji Suzuki, Takeshi Ogata, Soichi Sugiyama, Keiichiro Nakamura, Shoji Nagao, Hisashi Masuyama, Takao Hiraki

    Journal of radiation research   63 ( 5 )   772 - 779   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We analyzed the local control (LC) of cervical squamous cell carcinoma treated by computed tomography (CT)-based image-guided brachytherapy (IGBT) using central shielding (CS). We also examined the value of tumor diameter before brachytherapy (BT) as a factor of LC. In total, 97 patients were analyzed between April 2016 and March 2020. Whole-pelvic (WP) radiotherapy (RT) with CS was performed, and the total pelvic sidewall dose was 50 or 50.4 Gy; IGBT was delivered in 3-4 fractions. The total dose was calculated as the biologically equivalent dose in 2 Gy fractions, and distribution was modified manually by graphical optimization. The median follow-up period was 31.8 months (6.3-63.2 months). The 1- and 2-year LC rates were 89% and 87%, respectively. The hazard ratio was 10.11 (95% confidence interval: 1.48-68.99) for local recurrence in those with a horizontal tumor diameter ≥ 4 cm compared to those with < 4 cm before BT. In CT-based IGBT for squamous cell carcinoma, favorable LC can be obtained in patients with a tumor diameter < 4 cm before BT. However, if the tumor diameter is ≥ 4 cm, different treatment strategies such as employing interstitial-BT for dose escalation may be necessary.

    DOI: 10.1093/jrr/rrac040

    PubMed

    researchmap

  • Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis 査読 国際誌

    Kuniaki Katsui, Takeshi Ogata, Soichi Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Scientific Reports   11 ( 1 )   11882 - 11882   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    <title>Abstract</title>We intended to investigate whether muscle and adipose masses were associated with prognosis among patients with stage III non-small-cell lung cancer (NSCLC) who were undergoing chemoradiotherapy (CCRT). We retrospectively explored data of patients with stage III NSCLC who underwent definitive CCRT (≥ 60 Gy) between January 2004 and March 2018 at our hospital. We examined the relationship of overall survival (OS) with body mass index (BMI), skeletal muscle index (SMI), psoas muscle index (PMI), visceral adipose tissue index (VAI), subcutaneous adipose tissue index (SAI), and visceral-to-subcutaneous adipose tissue area ratio (VSR) using log-rank tests for the univariate analysis and Cox proportional hazard models for the multivariate analysis. Overall, 16, 32, and 12 patients had stage IIIA, IIIB, and IIIC NSCLC, respectively. The total radiotherapy dose ranged from 60 Gy/30 fractions to 66 Gy/33 fractions. In the univariate analysis, the performance status (PS), BMI, and SMI were associated with OS, whereas the PMI, VAI, SAI, and VSR were not. In the multivariate analysis, the PS and SMI were associated with OS. The hazard ratios and 95% confidence intervals were 2.91 and 1.28–6.64 for PS, and 2.36 and 1.15–4.85 for SMI, respectively. The 1, 3, and 5-year OS rates were 92.1%, 59.6%, and 51.0% in patients with high SMI, and 63.6%, 53.8%, and 17.9% in patients with low SMI, respectively. The SMI correlated with prognosis in our study population, whereas adipose mass did not. Therefore, sarcopenia should be considered while predicting the OS in such patients.

    DOI: 10.1038/s41598-021-91449-z

    PubMed

    researchmap

    その他リンク: http://www.nature.com/articles/s41598-021-91449-z

  • Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study 査読 国際誌

    Kenta Watanabe, Kuniaki Katsui, Soichiro Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Radiation Oncology   16 ( 1 )   39 - 39   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    <title>Abstract</title><sec>
    <title>Background</title>
    Stereotactic body radiation therapy (SBRT) is an established therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC). Many elderly patients are medically inoperable owing to comorbidities. Therefore, SBRT may be a useful therapy for elderly patients. However, the application of SBRT for patients aged ≥ 80 years has not been completely elucidated. Therefore, this study aimed to assess the clinical utility of SBRT for elderly patients aged ≥ 80 years with pathologically proven early-stage NSCLC.


    </sec><sec>
    <title>Methods</title>
    We retrospectively evaluated the data of patients aged ≥ 80 years with pathologically proven primary NSCLC who underwent SBRT at our institution between January 2009 and March 2020. Treatment outcomes and toxicities were analyzed. We used the Kaplan–Meier method to estimate survival curves and the log-rank test to compare the survival curves. We performed univariate and multivariate Cox regression analyses. <italic>p</italic>-values &lt; 0.05 were regarded significant.


    </sec><sec>
    <title>Results</title>
    Sixty-four patients (65 lesions) were included, and the median follow-up period was 38.7 (range 3.5–95.7) months. The median age was 82.9 (range 80.0–94.8) years. Sixteen patients were medically operable, and 48 patients were medically inoperable. The prescribed dose of SBRT was either 48 Gy in four fractions or 60 Gy in 10 fractions. The median survival time was 60.0 months (95% confidence interval, 43.5–71.1). The 1-, 3-, and 5-year local control, cancer-specific survival, progression-free survival, and overall survival rates were 98.4%, 98.4%, 81.0%, and 88.9%; 90.1%, 93.7%, 58.9%, and 68.3%; and 87.4%, 83.5%, 38.2%, and 47.5%, respectively. Multivariate analysis revealed that inoperability and solid nodules were the predictors of poor overall survival after SBRT in elderly patients. Two patients (3.1%) had grade 3 radiation pneumonitis, and one patient (1.6%) had grade 5 radiation pneumonitis.


    </sec><sec>
    <title>Conclusions</title>
    SBRT was feasible in patients aged ≥ 80 years with NSCLC. It achieved good local control with minimal toxicity. SBRT may be beneficial in elderly patients with early-stage NSCLC.


    </sec>

    DOI: 10.1186/s13014-021-01769-7

    PubMed

    researchmap

    その他リンク: http://link.springer.com/article/10.1186/s13014-021-01769-7/fulltext.html

  • Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer 査読

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Masaomi Yamane, Takao Hiraki, Katsuyuki Kiura, Shinichi Toyooka, Susumu Kanazawa

    International Journal of Clinical Oncology   26 ( 8 )   1450 - 1460   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    BACKGROUND: The association between sarcopenia and prognosis in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing trimodality therapy, consisting of preoperative concurrent chemoradiotherapy and surgery, has not been reported. Therefore, we aimed to investigate the association of sarcopenia and fat mass with prognosis after trimodality therapy. METHODS: To assess sarcopenia, the psoas muscle mass was measured. Using computed tomography data, including third lumbar vertebra level images, psoas muscle mass and visceral and subcutaneous fat mass were measured. Additionally, body mass indices, and visceral/subcutaneous fat ratio, obtained by dividing the visceral fat index by the subcutaneous fat index, were calculated. We investigated the relationship between these parameters and overall survival. RESULTS: Ninety-nine eligible patients were included. In the univariate analysis, age, clinical stage, tumor location, psoas muscle index, and visceral/subcutaneous fat ratio were significant prognostic factors for overall survival (P = 0.008, P = 0.04, P = 0.04, P = 0.02, and P = 0.02, respectively). In the multivariate analysis, age and psoas muscle index were significant prognostic factors for overall survival (P = 0.01 and P = 0.03, respectively). The 5-year overall survival rates for the high and low psoas muscle index groups were 79.6% [95% confidence interval (CI), 67.1-94.5%] and 66.2% (95% CI, 54.1-81.1%), respectively; whereas, the 10-year overall survival rates were 61.9% (95% CI, 42.0-91.4%) and 25.3% (95% CI, 8.6-74.2%), respectively. CONCLUSION: Sarcopenia was related to poor overall survival in patients with locally advanced NSCLC undergoing trimodality therapy. Assessment of body composition prior to treatment may provide important information for formulating rational therapeutic strategies.

    DOI: 10.1007/s10147-021-01927-7

    PubMed

    researchmap

    その他リンク: https://link.springer.com/article/10.1007/s10147-021-01927-7/fulltext.html

▼全件表示

MISC

  • III期非小細胞肺癌に対する化学放射線療法後の放射線肺臓炎の検討

    勝井 邦彰, 尾形 毅, 吉尾 浩太郎, 黒田 昌宏, 平木 隆夫, 木浦 勝行, 前田 嘉信, 豊岡 伸一, 金澤 右

    肺癌   60 ( 6 )   577 - 577   2020年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究発表ペーパー・要旨(全国大会,その他学術会議)   出版者・発行元:(NPO)日本肺癌学会  

    researchmap

  • 子宮頸がんに対する密封小線源治療の線量解析に関する検討

    大塚 裕太, 香川 義徳, 青山 英樹, 河合 佑太, 宇野 弘文, 田原 誠司, 片山 敬久, 井原 弘貴, 吉尾 浩太郎

    JART: 日本診療放射線技師会誌   65 ( 9 )   1064 - 1064   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本診療放射線技師会  

    researchmap

  • 同室CTを用いた子宮頸癌に対するIGBTの初期経験

    久住 研人, 片山 敬久, 杉山 聡一, 馬越 紀行, 渡邉 謙太, 井原 弘貴, 勝井 邦彰, 金澤 右, 依田 尚之, 中村 圭一郎, 平松 祐司, 吉尾 浩太郎

    Japanese Journal of Radiology   36 ( Suppl. )   55 - 55   2018年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本医学放射線学会  

    researchmap

  • SEVERE GASTROINTESTINAL BLEEDING IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA TREATED BY CONCURRENT RADIOTHERAPY AND CETUXIMAB

    Naoya Murakami, Seiichi Yoshimoto, Fumihiko Matsumoto, Takao Ueno, Yoshinori Ito, Kazuma Kobayashi, Ken Harada, Mayuka Kitaguchi, Shuhei Sekiii, Kana Takahashi, Kotaro Yoshio, Koji Inaba, Madoka Morota, Minako Sumi, Yutaka Saito, Jun Itami

    ANTICANCER RESEARCH   34 ( 10 )   6075 - 6075   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:INT INST ANTICANCER RESEARCH  

    Web of Science

    researchmap

  • Factors Influencing Pain Reduction: Bone Metastases From Renal Cell Carcinoma (RCC) Treated With Radiation Therapy

    K. Harada, K. Kobayashi, M. Kitaguchi, S. Sekii, K. Takahashi, K. Inaba, K. Yoshio, M. Morota, Y. Ito, M. Sumi, J. Itami

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   90   S695 - S695   2014年9月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ELSEVIER SCIENCE INC  

    Web of Science

    researchmap

▼全件表示

共同研究・競争的資金等の研究

  • 放射線性う蝕から歯を守る~頭頸部がんサバイバーのQOL向上のための基礎研究~

    研究課題/領域番号:23K07156  2023年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    松崎 久美子, 吉山 昌宏, 島田 康史, 青山 英樹, 松崎 秀信, 吉尾 浩太郎

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • 臓器の呼吸性移動を可視化する複合現実の開発:画像下低侵襲がん治療への実装に向けて

    研究課題/領域番号:23K07083  2023年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    松井 裕輔, 諸岡 健一, 平木 隆夫, 櫻井 淳, 吉尾 浩太郎, 冨田 晃司

      詳細を見る

    配分額:4550000円 ( 直接経費:3500000円 、 間接経費:1050000円 )

    researchmap

 

担当授業科目

  • 生殖系(臓器・系別統合講義) (2024年度) 特別  - その他

  • 腫瘍学 (2024年度) 特別  - その他

  • 臨床放射線総論 (2024年度) 特別  - その他

  • 腫瘍学 (2023年度) 特別  - その他